Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. | Following an inspection earlier this year that yielded a Form 483, Indian generics juggernaut Alembic Pharmaceuticals has received a harsher reprimand from the U.S. FDA.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Alembic Pharmaceuticals received an FDA warning letter for failing to label a bioequivalence study as

From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with…

Pfizer’s complaint about Alnylam’s activities at a cardiology congress has led the PMCPA to chastise the | Pfizer’s complaint…

The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading…

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…

In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has